Recent advancements in anti-CD19 CAR-T cell therapy have led to rapid and long-lasting responses in patients with relapsed or refractory (R/R) B-ALL and NHL, fundamentally changing treatment approaches for these conditions. Here, CD19 is linked to non-Hodgkin lymphoma.